Gilead Signs Generic Deals for Ebola Drug

Gilead Sciences has signed royalty-free agreements with three generic drugmakers to supply its experimental Ebola prevention drug to 127 low-income nations. The deals cover obeldesivir and aim to secure manufacturing capacity ahead of clinical trial results.

Xurve View
Insights:
Gilead logo is seen in this illustration taken August 5, 2025. REUTERS/Dado Ruvic/Illustration

Gilead Sciences signed royalty-free licensing deals with three generic manufacturers on Monday to supply its experimental Ebola drug to 127 low- and lower-middle-income nations. The agreements cover obeldesivir and target countries reporting cases in the active Ebola Bundibugyo outbreak. Preclinical trials show activity against Ebola-related viruses, positioning the company for pre-approval manufacturing scale-up.